Critical review of the major pharmacokinetic properties of the clinically approved toxin-derived peptide drugs and of their dependence on the peptides structure, of the major pharmacokinetic variability factors of the analyzed drugs, and their use for dose adjustment in the individual patients.

1. Introduction {#sec1-toxins-10-00483}
===============

Peptides are an important component of toxins and venoms produced by different organisms. They evolved to have highly selective and potent pharmacological effects on specific targets for protection and predation. These properties, and advances in the detection, analytics, and synthesis of peptides and their derivatives, make them promising leads for the development of new drugs \[[@B1-toxins-10-00483]\]. Indeed, several toxin-derived peptides have become drugs for the management of diabetes, hypertension, chronic pain, and other medical conditions \[[@B2-toxins-10-00483]\]. Dozens of toxin-derived peptides and their derivatives are undergoing clinical trials or are in the pre-clinical development stages.

Despite the similarity in their composition (amino acids as the building blocks), toxin-derived peptides have very profound differences in their structure and conformation. Only part of this "chemical space" can apparently lead to successful drug leads and new drugs. This is because the unfavorable physicochemical and pharmacokinetic (PK) properties of a drug candidate, even if it possesses a highly potent and selective desired pharmacological activity, can lead to failure in the pre-clinical and clinical development, or/and to substantial limitations in its clinical use.

The objective of this review is to critically summarize and analyze the pharmacokinetic properties of toxin-derived peptide drugs. Specifically, (1) to describe the relationship between the chemical structure, physicochemical properties, and the pharmacokinetics of the specific drugs, (2) summarize the major pharmacokinetic properties and parameters of these drugs, (3) to describe the major variability factors and extent of their effect on the pharmacokinetics of the individual drugs.

The focus of this review is on the drugs that were approved for clinical use (see [Table 1](#toxins-10-00483-t001){ref-type="table"} for the details of the analyzed drugs, including their origin, indication, and innovative drug products), and not on the agents that are evaluated currently in pre-clinical or clinical trials, or have been discontinued.

2. Structure and Physicochemical Properties of Clinically-Approved Toxin-Derived Peptide Drugs {#sec2-toxins-10-00483}
==============================================================================================

The chemical structures of the clinically approved toxin-derived peptide drugs are shown in [Figure 1](#toxins-10-00483-f001){ref-type="fig"}. It can be seen that there are profound differences in the structures of the individual agents: composition, size, the presence of intramolecular bonds/rings, conformation, etc. As a result, these agents possess very different physicochemical properties, some of which are summarized in [Table 2](#toxins-10-00483-t002){ref-type="table"}. Specifically, the molecular weight of the drugs varies profoundly between 217--4910 g/mol (please compare to the commonly-approved cutoff of 1000 g/mol for the small molecular weight (MW)-drugs). These drugs exist in numerous conformations, and for some of the molecules, the conformational space is limited by the cyclic structure or the presence of disulfide intramolecular bridges (see [Figure 1](#toxins-10-00483-f001){ref-type="fig"}).

These analyzed compounds contain in their sequence hydrophobic and hydrophilic amino acids, and the later ones (such as carboxylic acid and amine groups) can be charged at the physiological pH (see [Figure 1](#toxins-10-00483-f001){ref-type="fig"} and [Table 2](#toxins-10-00483-t002){ref-type="table"}). Overall, there are profound differences in the chemical structure of the analyzed compounds that affect the conformation, solubility, and stability of the specific compound, and its ability to interact with endogenous compounds (e.g., albumin and metabolic enzymes) and permeate biological membranes (e.g., the gastrointestinal wall or other biological barriers). In the next section, we will analyze the effect of the structural and physicochemical properties (see [Figure 1](#toxins-10-00483-f001){ref-type="fig"} and [Table 2](#toxins-10-00483-t002){ref-type="table"}) on the pharmacokinetics of the individual agents (see [Table 1](#toxins-10-00483-t001){ref-type="table"}), and the sources of pharmacokinetic variability in the individual patients that are treated with these drugs.

3. Pharmacokinetic Properties of the Clinically Approved Toxin-Derived Peptide Drugs {#sec3-toxins-10-00483}
====================================================================================

3.1. Captopril {#sec3dot1-toxins-10-00483}
--------------

Captopril is a small molecular weight drug that has been used clinically from the 1980s. It was the first orally active inhibitor of the angiotensin-converting enzyme, and it is still used widely in the treatment of hypertension and congestive heart failure \[[@B2-toxins-10-00483]\].

Due to its chemical structure and physicochemical properties, captopril has good solubility in water and gastrointestinal (GI) fluids (see [Table 2](#toxins-10-00483-t002){ref-type="table"}). However, its absorption is limited by its low permeability through the biological membranes (including the GI wall), and captopril is classified into Class III (high solubility, low permeability) \[[@B3-toxins-10-00483]\] of the biopharmaceutics classification system (BCS) \[[@B4-toxins-10-00483]\]. Overall, about 60% to 75% of an oral dose of captopril is absorbed (see [Table 3](#toxins-10-00483-t003){ref-type="table"}), and its peak blood concentrations are reached about 45 min to 60 min after oral administration \[[@B5-toxins-10-00483],[@B6-toxins-10-00483]\]. Co-administration with food decreases the bioavailability of captopril by 30--40%, and it is recommended to be given one hour before meals \[[@B5-toxins-10-00483]\]. However, the decreased bioavailability of captopril when taken with meals does not significantly alter clinical responses to the drug \[[@B6-toxins-10-00483]\].

Captopril contains a sulfhydryl group and binds to albumin and endogenous thiol-containing compounds (such as cysteine and glutathione) in the plasma and other body fluids. It also exists in a form of a disulfide dimer of the parent drug. These compounds (that are described collectively as "total captopril") serve as a reservoir of the pharmacologically-active drug, and prolong its pharmacological effect. Overall, approximately 30% of the captopril in the central circulation is bound to the plasma proteins, and its volume of distribution is 0.8 L/kg \[[@B6-toxins-10-00483]\] (that corresponds to 56 L in a 70-kg patient).

The clearance of captopril in healthy subjects is approximately 49 L/h, resulting in an elimination half-life of unchanged captopril of approximately 2 h. Captopril is eliminated from the body primarily by the kidneys, and undergoes active secretion in the tubuli of the nephron \[[@B5-toxins-10-00483],[@B6-toxins-10-00483]\]. Decreased renal function leads to accumulation of the drug in the body and necessitates dose reduction \[[@B5-toxins-10-00483],[@B7-toxins-10-00483]\] (see [Table 4](#toxins-10-00483-t004){ref-type="table"}). Similar phenomenon and the need for dose reduction are observed when captopril is administered with probenecid, which is apparently due to competition between these drugs for tubular secretion in the kidneys \[[@B6-toxins-10-00483]\]. Overall, the pharmacokinetics of captopril appear to be preserved in patients with hypertension and congestive heart failure, and are not affected by many concomitant medications \[[@B7-toxins-10-00483],[@B8-toxins-10-00483]\].

3.2. Cyclosporine {#sec3dot2-toxins-10-00483}
-----------------

Cyclosporine is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids that is produced by the fungus species *Beauveria nivea* (see [Table 1](#toxins-10-00483-t001){ref-type="table"} and [Figure 1](#toxins-10-00483-f001){ref-type="fig"}). It is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants, and in some patients with rheumatoid arthritis and psoriasis \[[@B9-toxins-10-00483]\]. Cyclosporine was introduced into the clinical practice in the early 1980s, and it has been gradually replaced in the last few years by the newer agents \[[@B10-toxins-10-00483]\] (such as tacrolimus, sirolimus, therapeutic antibodies, and other drugs).

Cyclosporine is classified as a BCS class II (low solubility, high permeability) drug \[[@B3-toxins-10-00483]\]. Following oral administration, the absorption of cyclosporine is incomplete, and the absolute bioavailability generally varies between 10--89%, and is dependent on the individual patient, the patient population, the formulation, concomitant treatments, diet, etc. Cyclosporine undergoes substantial first-pass metabolism in the GI wall and in the liver by the CYP3A4 enzyme. It is also a substrate of the P-glycoprotein (Pgp) and other efflux pumps (that are expressed in the GI wall, liver, kidneys, and other locations in the body) \[[@B10-toxins-10-00483]\].

Cyclosporine distributes extensively in the body, and the steady-state volume of distribution is 3--5 L/kg. The drug distribution in the blood is approximately 41% to 58% in erythrocytes, 33% to 47% in plasma, 5% to 12% in granulocytes, and 4% to 9% in lymphocytes \[[@B11-toxins-10-00483]\]. In plasma, cyclosporine binds primarily to lipoproteins and secondarily to albumin. Its unbound fraction in the plasma equals approximately 10%. The disposition of cyclosporine from blood is generally biphasic, with a terminal half-life of approximately 8.4 h (range 5--27 h) \[[@B9-toxins-10-00483],[@B11-toxins-10-00483]\].

The elimination of cyclosporine is primarily biliary with only 6% of the dose (parent drug and metabolites) excreted in urine. The clearance of cyclosporine is approximately 5--7 mL/min/kg in adult recipients of renal or liver allografts, and slightly lower in cardiac transplant patients. Substrates, inhibitors, and inducers of the CYP3A enzyme affect the bioavailability and the clearance of cyclosporine \[[@B9-toxins-10-00483]\]. Therefore, dozens of drugs and nutrients have pharmacokinetic interaction with cyclosporine, affect its concentrations, and can lead to inefficiency or the excessive toxicity of this drug.

The substantial intersubject and intrasubject pharmacokinetic variability of cyclosporine, in combination with its narrow therapeutic window, necessitate dosage adjustment based on the therapeutic monitoring of its trough blood concentrations \[[@B9-toxins-10-00483]\]. Body weight, the co-administration of inhibitors of CYP3A, and hematocrit appear to be the most important factors associated with the clearance of cyclosporine in transplant patients, which necessitate dose adjustment \[[@B11-toxins-10-00483],[@B12-toxins-10-00483]\] (see [Table 4](#toxins-10-00483-t004){ref-type="table"}). The genetic effects (e.g., CYP3A4 variant alleles) appear to have a minor effect on the pharmacokinetics of cyclosporine, and the genotyping of the patients is rarely applied to individualize and optimize the dosing of this drug \[[@B13-toxins-10-00483],[@B14-toxins-10-00483]\].

3.3. Eptifibatide {#sec3dot3-toxins-10-00483}
-----------------

Eptifibatide is a cyclic heptapeptide that reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to glycoprotein IIb/IIIa. Eptifibatide is indicated in patients with acute coronary syndrome and percutaneous coronary intervention (PCI), and the recommended dosing regimen is IV bolus of the drug followed by an IV infusion, at the doses adjusted by the patients' weight \[[@B15-toxins-10-00483]\].

The volume of distribution of eptifibatide in patients with coronary artery disease is about 185--260 mL/kg, and is somewhat higher (220--270 mL/kg) in healthy individuals \[[@B16-toxins-10-00483]\]. The drug in the plasma is present largely in an unbound form, and the plasma elimination half-life is approximately 2.5 h.

Clearance in patients with coronary artery disease is 55--58 mL/kg/h \[[@B15-toxins-10-00483]\]. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as the original drug or its metabolites \[[@B17-toxins-10-00483]\]. Moderate to severe renal impairment resulted in a \~50% reduction in total eptifibatide clearance and a corresponding doubling of plasma eptifibatide concentration \[[@B18-toxins-10-00483]\]. Therefore, it was recommended to reduce twofold the IV infusion component of eptifibatide in these patients. The IV bolus component of the dose is used to establish the desired (steady-state) eptifibatide concentrations, is not based on the value of the drug clearance (but rather on the volume of drug distribution), and should not be altered \[[@B18-toxins-10-00483]\].

The pharmacokinetics of eptifibatide apparently is not affected by the gender, but there are indications that the clearance declines with age (in the geriatric versus adult subjects) \[[@B15-toxins-10-00483]\].

3.4. Lepirudin {#sec3dot4-toxins-10-00483}
--------------

Lepirudin is a recombinant 65-aa hirudin derived from yeast cells, which bears some differences in its chemical structure from the natural hirudin \[[@B19-toxins-10-00483]\]. It binds to thrombin, blocks its thrombogenic activity, and is used for anticoagulation in patients with heparin-associated thrombocytopenia (HIT) and associated thromboembolic disease. The marketing of lepirudin was discontinued in 2012, apparently due to the commercial reasons.

Lepirudin is recommended to be administered by IV bolus followed by IV infusion \[[@B19-toxins-10-00483]\], but subcutaneous administration of the drug and its subsequent pharmacokinetics were also characterized \[[@B20-toxins-10-00483]\]. Following intravenous administration, the time course of lepirudin plasma concentrations follows a two-compartment model, with an initial half-life of approximately 10 min, and a terminal half-life of about 1.3 h in young healthy volunteers \[[@B19-toxins-10-00483],[@B20-toxins-10-00483]\]. At the steady state, the drug distribution is confined to the extracellular fluids (V = 12.2 L in the healthy young subjects). The volume of distribution of lepirudin increases to \~18 L in the elderly patients and in patients with renal impairment (CLcr, creatinine clearance \<80 mL/min), and increases substantially (32.1 L; highly variable parameter, %CV = 98.9%) in patients with heparin-induced thrombocytopenia \[[@B19-toxins-10-00483]\].

Lepirudin is eliminated by the kidneys (48% of the IV dose, mostly in the form of unchanged drug) and apparently also undergoes catabolic hydrolysis (proteolysis in the plasma and extracellular fluids) \[[@B20-toxins-10-00483]\]. Clearance of the drug is proportional to the kidney function, and proportional dosage reduction based on creatinine clearance is recommended in patients with renal impairment \[[@B19-toxins-10-00483]\]. In patients with heparin-induced thrombocytopenia, the drug clearance is reduced by 20--30%, as compared to the healthy subjects. The clearance of lepirudin in women is lower by 25% than in men. In elderly patients, the clearance of lepirudin is lower by 20% than in younger subjects, apparently due to the reduction of renal function with age \[[@B19-toxins-10-00483]\].

The anticoagulant effects of lepirudin should be monitored using an activated partial thromboplastin time (aPTT) test, or another appropriate diagnostic test \[[@B21-toxins-10-00483]\], and drug dosage should be adjusted based on the obtained results \[[@B19-toxins-10-00483],[@B20-toxins-10-00483],[@B22-toxins-10-00483]\].

3.5. Bivalirudin {#sec3dot5-toxins-10-00483}
----------------

Bivalirudin is a specific and reversible direct thrombin inhibitor, which is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA) \[[@B23-toxins-10-00483]\]. It is a synthetic, 20-amino acid peptide that is administered to the patients as an intravenous (IV) bolus dose followed by IV infusion \[[@B24-toxins-10-00483],[@B25-toxins-10-00483]\].

Similar to lepirudin (see the previous section), following intravenous administration, the time course of bivalirudin plasma concentrations follows a two-compartment model \[[@B26-toxins-10-00483]\]. At the steady state, the drug distribution is confined to the extracellular fluids (V = 14 L in the healthy young subjects).

Bivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage, with a half-life of 25 min in patients with normal renal function \[[@B27-toxins-10-00483]\]. The clearance of bivalirudin is dependent on the renal function \[[@B24-toxins-10-00483],[@B25-toxins-10-00483],[@B27-toxins-10-00483]\]. Clearance was similar for patients with normal renal function and mild renal impairment (60--89 mL/min). It was reduced approximately by 20% in patients with moderate to severe renal impairment, by 60% in severe renal impairment, and by approximately 80% in dialysis-dependent patients \[[@B27-toxins-10-00483]\]. Approximately 25% of the drug can be cleared by hemodialysis \[[@B23-toxins-10-00483]\].

The clearance of bivalirudin is not dependent on the administered dose or patients' gender \[[@B27-toxins-10-00483]\]. Patients' weights and renal function are the major factors for the selection of bivalirudin dosage, along with the monitoring of the anticoagulation status for dose adjustment \[[@B23-toxins-10-00483],[@B27-toxins-10-00483]\].

3.6. Ziconotide {#sec3dot6-toxins-10-00483}
---------------

Ziconotide is a synthetic 25-amino acid antagonist of the N-type calcium channel \[[@B28-toxins-10-00483]\]. This drug is delivered intrathecally (IT) and is indicated for the management of severe chronic pain in certain groups of patients \[[@B29-toxins-10-00483]\].

Ziconotide is formulated as a sterile, preservative-free, isotonic solution for IT administration using an appropriate microinfusion device \[[@B28-toxins-10-00483]\]. Following IT administration, the cerebrospinal fluid (CSF) volume of distribution of ziconotide (155 mL) is similar to the estimated total CSF volume \[[@B30-toxins-10-00483]\]. The drug is cleaved in the body by endopeptidases and exopeptidases, and its terminal half-life is approximately 4.6 h \[[@B29-toxins-10-00483]\]. Following IT administration, the ziconotide that leaves the brain and the spinal cord is effectively diluted in the body fluids and exerts low systemic exposure \[[@B29-toxins-10-00483]\].

Due to the special local administration route, the pharmacokinetics of IT ziconotide does not depend on the renal function, weight, gender, or other patient-related factors \[[@B28-toxins-10-00483],[@B29-toxins-10-00483],[@B31-toxins-10-00483]\].

3.7. Exenatide (IR and SR Formulations) {#sec3dot7-toxins-10-00483}
---------------------------------------

Exenatide is a 39-amino acid peptide amide, a glucagon-like peptide-1 (GLP-1) receptor agonist, that acts as an incretin-mimetic agent, enhances glucose-dependent insulin secretion, and exhibits additional antihyperglycemic pharmacological effects \[[@B32-toxins-10-00483]\]. Exenatide is used in the form of twice-daily subcutaneous (SC) injections of immediate release (IR) formulation (drug solution) to the patients with type 2 diabetes.

The absolute bioavailability of IR exenatide following SC administration has not been reported, but apparently it is close to 100%, based on the recent population-based pharmacokinetic modeling analysis of clinical data from eight trials \[[@B33-toxins-10-00483]\]. The drug absorption following SC administration is rapid, and maximal plasma concentrations are attained approximately two hours after the injection. The apparent volume of distribution following SC administration is 28.3 L, and it is dependent on the body weight \[[@B33-toxins-10-00483]\].

Exenatide is predominantly eliminated by glomerular filtration and proteolytic degradation. The mean apparent clearance of exenatide is 9.1 L/h, and the mean terminal half-life is 2.4 h. In patients with mild to moderate renal impairment (creatinine clearance 30 mL/min to 80 mL/min), exenatide clearance is only mildly reduced, and no dose adjustment is necessary \[[@B34-toxins-10-00483]\]. However, a 10-fold reduction in exenatide apparent clearance was observed in patients with end-stage renal disease receiving dialysis (in comparison to the healthy subjects), necessitating a substantial dose reduction. The pharmacokinetics of exenatide is not affected substantially by the hepatic insufficiency \[[@B35-toxins-10-00483]\], gender, race, obesity, and advanced age (in geriatric patients), and these factors do not require a dose adjustment of the drug \[[@B36-toxins-10-00483]\].

Once-weekly (sustained release, SR) exenatide formulation contains the same drug that is encapsulated in the microspheres made of a biodegradable poly ([d,l]{.smallcaps}-lactide-co-glycolide) (PLGA) polymer \[[@B37-toxins-10-00483]\]. These microspheres should be resuspended (manually, or using a dual-chamber pen) prior to the SC injection to the patient \[[@B38-toxins-10-00483]\]. Exenatide is released at a constant rate from the injected microspheres; the steady state as attained after six to seven weeks, and the concentrations of the drug in the plasma decrease gradually over three months upon treatment discontinuation \[[@B37-toxins-10-00483]\]. The released drug follows the same distribution and elimination processes as the IR injection \[[@B39-toxins-10-00483]\], and apparently is affected by the same variability factors (body weight for the distribution, and renal function for the clearance; see above).

3.8. Lixisenatide {#sec3dot8-toxins-10-00483}
-----------------

Lixisenatide is a 44-amino acid peptide, a glucagon-like peptide-1 (GLP-1) receptor agonist, with the same pharmacological effects as exenatide \[[@B40-toxins-10-00483]\] (see above). Lixisenatide should be administered once daily as SC injections of immediate release formulation (drug solution).

The absolute bioavailability of lixisenatide following SC administration has not been reported. The drug absorption following SC administration is rapid, and maximal plasma concentrations are attained 1--3.5 h after the injection. The apparent volume of distribution (V/F) following SC administration is approximately 100 L, and it is dependent on the body weight \[[@B41-toxins-10-00483]\].

Lixisenatide is eliminated by glomerular filtration and proteolytic degradation. The mean apparent clearance (CL/F) of the drug is 35 L/h and the mean terminal half-life is three hours. Mild, moderate, and severe renal impairment lead to increased maximal plasma concentrations (C~max~, by 60%, 42% and 83%, accordingly) and area under plasma concentration vs. time curve (AUC, by 34%, 69% and 124%, accordingly) values of lixisenatide \[[@B40-toxins-10-00483]\]. Indeed, creatinine clearance was identified as a covariate for the apparent clearance of lixisenatide based on the population-based pahrmacokinetic modeling analysis \[[@B41-toxins-10-00483]\]. Despite this, no dose adjustment of lixisenatide is recommended in patients with mild and moderate renal impairment \[[@B34-toxins-10-00483],[@B40-toxins-10-00483]\], but close monitoring of drug safety (the GI adverse effects and renal functions) in these patients is advised. Use of the drug in patients with end-stage renal disease is not recommended.

The pharmacokinetics of lixisenatide is not affected substantially by the hepatic insufficiency \[[@B35-toxins-10-00483]\], gender, race, body weight, and advanced age (in geriatric patients) \[[@B42-toxins-10-00483]\], and these factors do not require any dose adjustment of the drug.

3.9. Linaclotide {#sec3dot9-toxins-10-00483}
----------------

Linaclotide is a 14-amino acid peptide for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C) \[[@B43-toxins-10-00483]\]. Linaclotide acts on the guanylate cyclase-C (GC-C) receptors on the luminal membrane of the GI tract to increase chloride and bicarbonate secretions into the intestine; it also inhibits the absorption of sodium ions, thus increasing the secretion of water into the lumen and improving defecation \[[@B44-toxins-10-00483],[@B45-toxins-10-00483],[@B46-toxins-10-00483]\].

The absorption of linaclotide into the systemic circulation is minimal, and only a few patients that received the regular oral doses of linaclotide had detectable plasma drug concentrations \[[@B43-toxins-10-00483]\]. In the GI tract, linaclotide is metabolized to the active 13-amino acid metabolite, MM-419447 (des-tyrosine) by the removal of the C-terminal tyrosine \[[@B47-toxins-10-00483]\]. After the standard oral doses, concentrations of linaclotide and its active metabolite in plasma are below the limit of quantitation. Therefore, standard pharmacokinetic parameters cannot be calculated for these compounds \[[@B43-toxins-10-00483]\]. Both linaclotide and its metabolite are proteolytically degraded in the intestinal lumen to smaller peptides and natural amino acids.

Neither linaclotide nor its active metabolite are inhibitors or inducers of cytochrome P450 enzymes, or inhibitors of common human efflux or uptake transporters \[[@B46-toxins-10-00483],[@B48-toxins-10-00483]\]. The lack of absorption, local action in the gastrointestinal tract, and proteolytic metabolism mean that age, gender, renal impairment, and hepatic impairment do not alter the pharmacokinetics of oral linaclotide \[[@B43-toxins-10-00483],[@B46-toxins-10-00483],[@B48-toxins-10-00483]\].

3.10. Plecanatide {#sec3dot10-toxins-10-00483}
-----------------

Plecanatide is a 16-amino acid peptide for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C) \[[@B49-toxins-10-00483],[@B50-toxins-10-00483],[@B51-toxins-10-00483]\]. Similar to linaclotide (see the previous section), plecanatide and its active metabolite act locally on the luminal membrane of the GI tract, and are minimally absorbed into the systemic circulation \[[@B49-toxins-10-00483],[@B50-toxins-10-00483],[@B51-toxins-10-00483]\]. Thus, standard pharmacokinetic parameters cannot be calculated for these compounds, and dose adjustment of plecanatide based on the common variability factors is not necessary.

4. Concluding Remarks and Perspectives {#sec4-toxins-10-00483}
======================================

The clinically approved toxin-derived peptide drugs are very dissimilar in many respects. They originate from different species and affect very different targets at different locations in the body (see [Table 1](#toxins-10-00483-t001){ref-type="table"}). This necessitates their administration via different routes, including the most common and convenient oral route (for local effects---linaclotide and plecanatide; or for systemic effects---captopril and cyclosporine), and one of the least convenient and invasive routes of administration---an intrathecal infusion mode (for ziconotide).

Based on their chemical structure (see [Figure 1](#toxins-10-00483-f001){ref-type="fig"}), clinically approved toxin-derived peptide drugs can be classified into peptides or peptide-derived drugs (such as captopril); they can also be classified into linear or cyclic compounds, which contain or lack intramolecular disulfide bridges (see [Figure 1](#toxins-10-00483-f001){ref-type="fig"} and [Table 2](#toxins-10-00483-t002){ref-type="table"}). Of course, these structural differences have a profound effect on the physicochemical properties of the analyzed drugs, only some of which are summarized in this review (see [Table 2](#toxins-10-00483-t002){ref-type="table"}).

Molecular weight appears to be one of the most important properties of the analyzed toxin-derived peptide drugs, since it directly affects the suitability of the specific compound for oral administration to the patients, and their subsequent pharmacokinetics. The relatively high molecular weight of linaclotide and plecanatide, combined with their limited water solubility (see [Table 2](#toxins-10-00483-t002){ref-type="table"}), are beneficial for their local effect within the GI lumen after oral administration. The combination of these properties limits the systemic absorption of linaclotide and plecanatide (see [Table 3](#toxins-10-00483-t003){ref-type="table"}) that contributes to their selectivity and safety. On the other hand, a similar combination of properties for cyclosporine is undesired, since it limits the absorption of the drug after oral administration and contributes to the high pharmacokinetic variability of this drug (see [Table 4](#toxins-10-00483-t004){ref-type="table"}).

For the toxin-derived peptide drugs that are administered intravenously and locally (eptifibatide, lepirudin, bivalirudin, and ziconotide), high molecular weight is not a limitation, and can be advantageous, because it limits the distribution of the drug from the site of administration to other locations in the body. Indeed, all of the above-mentioned drugs have small volumes of distribution, and exert their desired pharmacological effect at the administration site. For instance, the IV-administered drugs (eptifibatide, lepirudin, and bivalirudin) have a volume of distribution values in the range of 12--19 L (see [Table 3](#toxins-10-00483-t003){ref-type="table"}), indicating their distribution in the blood and in the extracellular fluid, and exert their effects within the blood vessels (inhibition of platelet aggregation or of thrombosis; see [Table 1](#toxins-10-00483-t001){ref-type="table"}). Ziconotide distributes in the brain, which is the site of the desired effect (management of chronic pain; see [Table 1](#toxins-10-00483-t001){ref-type="table"}), and exerts low systemic exposure following intrathecal infusion.

A small volume of drug distribution, which characterizes many toxin-derived peptide drugs (see [Table 3](#toxins-10-00483-t003){ref-type="table"}), indicates that these drugs can undergo efficient elimination by the clearing organs (kidney and liver). Indeed, renal elimination is a major pathway of clearance for the analyzed drugs, and renal function-based (CLcr) dosage adjustment is needed for many of them to avoid toxicity (see [Table 4](#toxins-10-00483-t004){ref-type="table"}). An additional major elimination pathway, which is characteristic for all of the toxin-derived peptide drugs, is proteolysis by proteases that are abundant in different locations in the body. Therefore, proteolysis affects peptide drugs at the sites of their administration and distribution, irrespective of whether their volume of distribution is small or big.

A small volume of drug distribution, combined with efficient clearance via renal and proteolytic routes (see above), results in short half-life values for all of the analyzed toxin-derived peptide drugs (see [Table 3](#toxins-10-00483-t003){ref-type="table"}). For IV-administered drugs that affect a critical pathway (blood clotting), such a short half-life is advantageous, since it allows a tight control of this pathway by changing the drug infusion rate. On the other hand, a short half-life requires continuous drug infusion under medical supervision, which can be inconvenient to the patient. This drawback is especially pronounced for ziconotide, which is infused intrathecally using special catheters and microinfusion devices.

A short half-life can be disadvantageous also for the subcutaneously-administered anti-diabetic agents, despite prolonged duration of their pharmacological effects that continue also after elimination of the drug from the body. A standard dosing of exenatide and lixisenatide requires twice-daily and single-daily SC injections, which are inconvenient for the patients. To overcome this limitation, once-weekly SR formulation has been developed for exenatide (see [Section 3.7](#sec3dot7-toxins-10-00483){ref-type="sec"} above).

To summarize, the chemical structure of toxin-derived peptide drugs has specific effects on their pharmacokinetics. These drugs tend to have limited permeability via biological barriers, leading to a low volume of their distribution, and the need to administer them invasively (via IV, SC, or intrathecal route). These drugs are eliminated efficiently via the kidneys and proteolytic degradation, leading to their short half-life and the need for frequent or continuous dosing. The dose of many toxin-derived peptide drugs should be adjusted in the case of renal insufficiency, and monitoring patients' renal function (CLcr) is needed to maintain the desired efficacy/safety balance of these drugs.

There are additional consequences of the chemical structure of toxin-derived peptide drugs that were not covered in this review. For instance, the peptide nature of these drugs is a challenge for their manufacture; it limits the stability (shelf-life) of their drug products, necessitates specific shipment and storage conditions, etc. The pharmacodynamic aspects of toxin-derived peptide drugs were mentioned only in a superficial way in this review. The high potency of these drugs, which stems from their origin (toxins), affects their safety (i.e., the balance of their desired versus adverse effects) the selection of doses, and dose adjustment in the individual patients.

This review focused only on the toxin-derived peptides that were approved for clinical use. Several agents from this group were discontinued in clinical trials stage (e.g., α-conotoxin Vc1.1, χ-conotoxin-MrIA, contulakin-G, conantokin-G, cenderitide and others; these are reviewed by Pennington et al. in \[[@B2-toxins-10-00483]\]). Clinical development of the majority of these peptides was discontinued because of toxicity-related issues, and not because of unfavorable pharmacokinetic properties. Overall, it appears that the chemical structure of a specific toxic peptide can be a useful source for the development of toxin-derived peptide drugs. Exploration of the "chemical space" of a specific toxin and its extensive modification using the available techniques (e.g., by changing the amino acid sequence, cyclization, introducing additional chemical groups, etc.; see [Figure 1](#toxins-10-00483-f001){ref-type="fig"}) can lead to the acceptable (or even desirable) combination of the physicochemical and pharmacokinetic properties for the subsequent pre-clinical and clinical development of toxin-derived drug leads. The toxicity of some toxin-derived agents is expected, and unfortunately cannot be avoided completely at the different stages of drug development.

Overall, toxin-derived peptides are a heterogeneous, interesting, and promising group of agents that can be suitable for many clinical applications. They have specific structural properties that affect their pharmacokinetics and pose some limitations on their clinical use. These properties should be taken into account during the development of new toxin-derived peptide drugs and for the efficient and safe use of the clinically approved drugs from this group in individual patients.
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toxins-10-00483-t001_Table 1

###### 

Summary of the clinically-approved toxin-derived peptide drugs and of their innovative drug products.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug           Derives From                                                                             Mechanism of Action                                                         Major Indication                  Innovator Product/s                        Major Doses and Formulation/s                                           Administration Route           Innovator Company                  Approved for Clinical Use in
  -------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------- --------------------------------- ------------------------------------------ ----------------------------------------------------------------------- ------------------------------ ---------------------------------- ---------------------------------------
  Captopril      Bradykinin-potentiating factor from the venom of a lancehead viper (Bothrops jararaca)   angiotensin-converting enzyme (ACE) inhibitor                               hypertension                      Capoten                                    6.25 mg, 12.5 mg, 25 mg, 50 mg, and 100 mg tablets                      PO                             Bristol Myers Squibb               1981

  Cyclosporine   *Tolypocladium inflatum* fungus                                                          calcineurin inhibitor                                                       immunosuppression                 Sandimmune, Neoral                         10 mg, 25 mg, and 100 mg solution or capsules                           PO                             Novartis                           1983

  Eptifibatide   Pigmy rattlesnake\                                                                       reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor   platelet aggregation inhibition   Integrilin                                 0.75 mg and 2 mg solution                                               IV                             Merck Ltd.                         1999
                 (*Sistrurus miliarius*)                                                                                                                                                                                                                                                                                                                                                                     

  Lepirudin      European medicinal leech (*Hirudo medicinalis*)                                          thrombin inhibitor                                                          prevention of thrombosis          Refludan                                   20 mg and 50 mg solution                                                IV                             Bayer Healthcare Pharmaceuticals   1997 (manufacture terminated in 2012)

  Bivalirudin    thrombin inhibitor                                                                       prevention of thrombosis                                                    Angiomax                          250 mg solution                            IV                                                                      The Medicines Company          2000                               

  Ziconotide     Magical cone marine snail (*Conus magus*)                                                selective N-type voltage-gated calcium channel blocker                      chronic pain                      Prialt                                     25 ug and 100 ug solution                                               Intrathecal                    Elan Pharmaceuticals               2004

  Exenatide      Gila monster lizard\                                                                     glucagon-like peptide-1 (GLP-1) receptor agonist                            type 2 diabetes                   Bydureon, Byetta                           5 mg, 10 mg, 250 ug, and 2 mg solution or extended release suspension   SC                             Astra Zeneca                       2011
                 (*Heloderma suspectum*)                                                                                                                                                                                                                                                                                                                                                                     

  Lixisenatide   glucagon-like peptide-1 (GLP-1) receptor agonist                                         type 2 diabetes                                                             Adlyxin, Lyxumia                  10 ug, 20 ug, 50 ug, and 100 ug solution   SC                                                                      Sanofi-Aventis                 2016                               

  Linaclotide    Heat-stable\                                                                             guanylate cyclase-C agonist                                                 constipation                      Linzess, Constella                         72.5 ug, 145 ug, and 290-ug capsules                                    PO                             Allergan Pharmaceuticals           2012
                 enterotoxin from the pathogenic *E. coli*                                                                                                                                                                                                                                                                                                                                                   

  Plecanatide    guanylate cyclase-C agonist                                                              constipation                                                                Trulance                          3 mg immediate release tablets             PO                                                                      Synergy Pharmaceuticals Inc.   2017                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

toxins-10-00483-t002_Table 2

###### 

The major physicochemical properties of the clinically approved toxin-derived peptide drugs. MW: molecular weight.

  ----------------------------------------------------------------------------------------------------------------------------
  Drug           MW     Number of Amino Acids and Structural Features       Physiological Charge   logP    Water Solubility\
                                                                                                           mg/mL
  -------------- ------ --------------------------------------------------- ---------------------- ------- -------------------
  Captopril      217    1, with coordinating sulfhydryl-containing moiety   −1                     0.34    4.52

  Cyclosporine   1203   11, cyclic                                          \-                     3.64    0.04

  Eptifibatide   832    7, cyclic                                           \-                     \-      1

  Lepirudin      6963   65, with 3 disulfide bridges                        \-                     \-      freely soluble

  Bivalirudin    2180   20                                                  −4                     −0.76   0.0464

  Ziconotide     2639   25, with 3 disulfide bridges                        \-                     \-      freely soluble

  Exenatide      4187   39                                                  \-                     \-      3

  Lixisenatide   4910   44                                                  −6                     4.15    6

  Linaclotide    1527   14, with 3 disulfide bridges                        −1                     −1.5    0.701

  Plecanatide    1682   16, with 2 disulfide bridges                        −8                     0.64    0.165
  ----------------------------------------------------------------------------------------------------------------------------

toxins-10-00483-t003_Table 3

###### 

The major pharmacokinetic parameters of the clinically approved toxin-derived peptide drugs (in a typical adult 70-kg patient with normal renal function).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug           Absolute Bioavailability, F                                         Volume of Distribution, V or Apparent V (V/F)\       f~u~ %   Clearance, CL or Apparent CL (CL/F)\   t~1/2~\    T~max~\
                                                                                     L                                                             L/h                                    h          h
  -------------- ------------------------------------------------------------------- ---------------------------------------------------- -------- -------------------------------------- ---------- ----------
  Captopril      60--75% (PO)                                                        56                                                   65--70   49                                     2          0.75--1

  Cyclosporine   10--89% (variable, PO)                                              210--350                                             10       21--29                                 5--27      1.5--2.0

  Eptifibatide   100% (IV)                                                           13--18 (coronary artery disease)15.4--19 (healthy)   75       3.85                                   2.5        \-

  Lepirudin      100% (IV)                                                           12.2                                                 \-       9.8                                    1.3        \-

  Bivalirudin    100% (IV)                                                           14                                                   \-       14.3                                   0.42       \-

  Ziconotide     50% (intrathecal)                                                   0.155                                                \-       \-                                     2.9--6.5   \-

  Exenatide      100% (SC)                                                           28.3                                                 \-       9.1                                    2.4        2.1

  Lixisenatide   -(SC)                                                               100                                                  45       35                                     3          1--3.5

  Linaclotide    \~0% (PO, local activity in the GI, is not absorbed systemically)   \-                                                   \-       \-                                     \-         \-

  Plecanatide    \~0% (PO local activity in the GI, is not absorbed systemically)    \-                                                   \-       \-                                     \-         \-
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

toxins-10-00483-t004_Table 4

###### 

The major pharmacokinetic variability factors, and their use for dose adjustment of the clinically approved toxin-derived peptide drugs.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                                          Variability Factor                                                                                                                                                          Dose Adjustment
  ----------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Captopril                                                                     dimerization and interaction with endogenous thiol-containing compounds in the plasma                                                                                       \-

  active tubular secretion in the kidneys                                       dose reduction in renal insufficiency                                                                                                                                       

  Cyclosporine                                                                  body weight                                                                                                                                                                 therapeutic monitoring of trough blood concentrations\
                                                                                                                                                                                                                                                            dosage adjustment taking into account the variability factors

  co-administration of inhibitors of CYP3A                                                                                                                                                                                                                  

  hematocrit                                                                                                                                                                                                                                                

  and additional factors                                                                                                                                                                                                                                    

  Eptifibatide                                                                  renal elimination of the drug                                                                                                                                               maintain the IV bolus component and reduce the IV infusion component of the dosage regimen in patients with renal insufficiency

  Lepirudin                                                                     renal elimination of the drug                                                                                                                                               dose selection based on patients' weight\
                                                                                                                                                                                                                                                            dose reduction in renal insufficiency\
                                                                                                                                                                                                                                                            monitoring of anticoagulant effects (aPTT test)

  gender, age, and disease state affect the drug distribution and elimination                                                                                                                                                                               

  Bivalirudin                                                                   renal elimination of the drug                                                                                                                                               dose selection based on patients' weight\
                                                                                                                                                                                                                                                            dose reduction in renal insufficiency\
                                                                                                                                                                                                                                                            monitoring of anticoagulant effects (aPTT test)

  Ziconotide                                                                    not reported                                                                                                                                                                \-

  Exenatide                                                                     body weight                                                                                                                                                                 \-

  renal elimination of the drug                                                 dose reduction in renal insufficiency                                                                                                                                       

  Lixisenatide                                                                  body weight                                                                                                                                                                 \-

  renal elimination of the drug                                                 no dose reduction, but close monitoring of drug safety, in mild or moderate renal impairment; use of the drug in patients with end stage renal disease is not recommended   

  Linaclotide                                                                   not reported                                                                                                                                                                \-

  Plecanatide                                                                   not reported                                                                                                                                                                \-
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
